Triple Negative Breast Cancer: From Mechanisms to Therapeutic Approaches

Dear Colleagues,

It has been known for several years that the descriptor “Triple negative breast cancer (TNBC)” is a catch-all phrase for a constellation of distinct disease entities that share in common an absence of ER and PR expression and lack amplification of the HER2 gene. The prohibitive intra-tumoral and inter-tumor heterogeneity that typifies this group of breast tumors has also made the stratification of TNBC into biomarker-positive actionable subgroups a critical step that drives treatment decisions. Thus, deciphering the tumor biology and understanding the molecular vulnerabilities for various TNBC subgroups, right-sizing systemic therapies, and improving risk stratification (beyond residual disease burden and extent) are crucial, alongside advancements in drug discovery and development, for identifying optimal precision treatments, both in neoadjuvant and adjuvant settings.

For this Special Issue, we welcome original research papers and review articles focused on promising mechanism-informed therapies for TNBC, including, but not limited to, the following:

• HER2- and TROP2- based antibody-drug conjugates;
• Novel immune checkpoint inhibitors;
• Molecules targeting dsDNA repair pathways;
• Inhibitors of cell cycle regulators;
• Angiogenesis inhibitors;
• Agents that target microtubule dynamics;
• Agents that target centrosome clustering pathways;
• Notch pathway and FGFR inhibitors;
• EGFR inhibitors;
• PIK3K/AKT/mTOR inhibitors;
• Epigenetic modifiers;
• Monoclonal antibodies;
• Therapeutic vaccines;
• Endocrine therapies;
• Chemotherapies.

Dr. Emad Rakha
Dr. Padmashree Rida
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.